DK1492561T3 - Fremgangsmåde til behandling af brystkirtellidelser - Google Patents

Fremgangsmåde til behandling af brystkirtellidelser

Info

Publication number
DK1492561T3
DK1492561T3 DK03815338T DK03815338T DK1492561T3 DK 1492561 T3 DK1492561 T3 DK 1492561T3 DK 03815338 T DK03815338 T DK 03815338T DK 03815338 T DK03815338 T DK 03815338T DK 1492561 T3 DK1492561 T3 DK 1492561T3
Authority
DK
Denmark
Prior art keywords
mammary gland
gland disorders
treating mammary
treating
disorders
Prior art date
Application number
DK03815338T
Other languages
Danish (da)
English (en)
Inventor
Mitchell F Brin
Stephen Donovan
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32867445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1492561(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK1492561T3 publication Critical patent/DK1492561T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Peptides Or Proteins (AREA)
  • Processing Of Meat And Fish (AREA)
DK03815338T 2002-02-08 2003-02-04 Fremgangsmåde til behandling af brystkirtellidelser DK1492561T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/071,826 US7838007B2 (en) 1999-12-07 2002-02-08 Methods for treating mammary gland disorders

Publications (1)

Publication Number Publication Date
DK1492561T3 true DK1492561T3 (da) 2006-09-25

Family

ID=32867445

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03815338T DK1492561T3 (da) 2002-02-08 2003-02-04 Fremgangsmåde til behandling af brystkirtellidelser

Country Status (12)

Country Link
US (2) US7838007B2 (fr)
EP (3) EP1492561B1 (fr)
JP (2) JP4889220B2 (fr)
AT (1) ATE331527T1 (fr)
AU (1) AU2003225549B2 (fr)
BR (1) BR0307496A (fr)
CA (1) CA2478902C (fr)
DE (1) DE60306505T2 (fr)
DK (1) DK1492561T3 (fr)
ES (1) ES2264041T3 (fr)
PT (1) PT1492561E (fr)
WO (1) WO2004071525A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US7838007B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
CA2413301A1 (fr) * 2000-06-28 2002-01-03 Ira Sanders Procedes d'utilisation de toxine tetanique a des fins therapeutiques chez des animaux (mammiferes)
CA2496005C (fr) * 2002-08-19 2013-07-23 Ira Sanders Traitement d'un dysfonctionnement de la glande holocrine au moyen de neurotoxines clostridiales
US20120114697A1 (en) * 2002-08-19 2012-05-10 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US7824693B2 (en) 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
WO2004066928A2 (fr) * 2003-01-24 2004-08-12 Albert Einstein College Of Medicine Of Yeshiva University Utilisation de vaccins a mycobacteries chez des mammiferes presentant une deficience en lymphocytes cd4+ et/ou cd8+.
EP2633856A3 (fr) * 2003-05-09 2014-01-01 The Trustees of The University of Pennsylvania Inhibiteurs de lyase de citrate d'ATP pour le traitement du cancer
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
US20070258900A1 (en) * 2004-07-20 2007-11-08 Joseph Francis Blood Flow Assessment of Clostridial Toxin Applications
EP1778078A2 (fr) * 2004-07-20 2007-05-02 Allergan, Inc. Evaluation thermographique d'applications de toxine clostridiale
US8343929B2 (en) * 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
ES2548152T3 (es) 2004-09-23 2015-10-14 Toxcure, Inc. Tratamiento de neoplasmas con neurotoxina
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US8155408B2 (en) * 2008-04-15 2012-04-10 General Electric Company Standardized normal database having anatomical phase information
EP2370090B1 (fr) 2008-11-26 2016-05-25 Toxcure, Inc. Traitement de néoplasmes avec une neurotoxine
US8629103B2 (en) 2010-12-02 2014-01-14 New York University Treatment of non-proliferative cystic disease of the breast
WO2012097189A1 (fr) * 2011-01-13 2012-07-19 Rutgers, The State University Of New Jersey Systèmes et procédés pour l'enregistrement multiprotocole et la classification de tissus utilisant une échelle morphologique locale
CA2841917A1 (fr) 2011-07-14 2013-01-17 Allergan, Inc. Procedes pour le traitement de l'incontinence associee a l'activite sexuelle
EP2836193B1 (fr) 2012-04-13 2018-01-31 Lubrizol Advanced Materials, Inc. Composés inhibant l'exocytosis neuronale (ii)
EP2649984A1 (fr) 2012-04-13 2013-10-16 Lipotec, S.A. Composés qui inhibent l'exocytosis neuronale
EP2649985A1 (fr) 2012-04-13 2013-10-16 Lipotec, S.A. Composés inhibant l'exocytosis neuronale (III)
EP2649983A1 (fr) 2012-04-13 2013-10-16 Lipotec, S.A. Composés inhibant l'exocytosis neuronale (II)
EP3843777A4 (fr) 2018-08-28 2022-05-04 Ira Sanders Agents thérapeutiques pour la peau

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5466672A (en) 1992-12-04 1995-11-14 Ophidian Pharmaceuticals, Inc. Therapeutic use of clostridium difficile toxin A
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
DE69526340T2 (de) 1994-05-09 2002-11-14 William J Binder Botulinumtoxin ZUR REDUKTION VON Migraine -KOPFSCHMERZEN
US5595740A (en) 1994-05-16 1997-01-21 University Of Florida Cloning of non-IgA FC binding forms of the group B streptococcal beta antigens
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
CN1321683C (zh) * 1997-07-15 2007-06-20 科罗拉多大学董事会 神经毒素疗法在泌尿系及相关疾病治疗中的应用
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
DE19802569A1 (de) 1998-01-23 1999-09-09 Univ Albert Ludwigs Freiburg Toxikologisch aktive Fragmente des lethalen Toxins von Clostridium sordellii und deren Verwendung in Immuntoxinen
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
MXPA01004254A (es) 1998-10-27 2002-04-24 Mayo Foundation Metodos para intensificar la curacion de heridas.
DE19852981A1 (de) 1998-11-17 2000-05-18 Martin Schmidt Botulinum-Toxine, deren Derivate, Analoge und molekulare Bruchstücke zur topischen epicutanen Anwendung auch in Zusammenwirken mit hautpenetrationsfördernden Substanzen und Maßnahmen in Zubereitungsformen zur Beeinflussung acetylcholinabhängiger Körperfunktionen
DE19856052A1 (de) 1998-12-04 2000-06-08 Deutsches Krebsforsch Konjugat zur Anreicherung in neuronalen Zellen
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
WO2000062746A1 (fr) 1999-04-16 2000-10-26 Marvin Schwartz Procede permettant de reduire la chute des cheveux et de stimuler la repousse capillaire
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US7838007B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
AU2001276005A1 (en) 2000-08-02 2002-02-13 Allergan Sales, Inc. Method for treating a neoplasm
US6831059B2 (en) 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses

Also Published As

Publication number Publication date
AU2003225549B2 (en) 2006-11-16
WO2004071525A1 (fr) 2004-08-26
EP2204183A1 (fr) 2010-07-07
EP1728517A3 (fr) 2008-06-25
ES2264041T3 (es) 2006-12-16
JP2012025775A (ja) 2012-02-09
EP1728517A2 (fr) 2006-12-06
ATE331527T1 (de) 2006-07-15
DE60306505D1 (de) 2006-08-10
CA2478902A1 (fr) 2004-08-26
US7838007B2 (en) 2010-11-23
US7846456B2 (en) 2010-12-07
EP1492561A1 (fr) 2005-01-05
BR0307496A (pt) 2005-06-28
US20050260231A1 (en) 2005-11-24
DE60306505T2 (de) 2007-01-11
JP2006510723A (ja) 2006-03-30
US20020094339A1 (en) 2002-07-18
JP4889220B2 (ja) 2012-03-07
PT1492561E (pt) 2006-10-31
AU2003225549A1 (en) 2004-09-06
EP1492561B1 (fr) 2006-06-28
CA2478902C (fr) 2012-05-01

Similar Documents

Publication Publication Date Title
DK1492561T3 (da) Fremgangsmåde til behandling af brystkirtellidelser
DK1401498T3 (da) Anti-NGF-antistoffer til behandlingen af forskellige sygdomme
DE60223923D1 (de) Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
BR0114054A (pt) Método para tratar alergias usando pirazóis substituìdos
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
DK1505990T3 (da) Fremgangsmåder til behandling af hepatitis
DE602004008329D1 (de) Botulinustoxin-therapie für hauterkrankungen
DK1696931T3 (da) Amino-substituerede diaryl[A,D]cyclohepten-analoger som muskarinske agonister og fremgangsmåder til behandling af neuropsykiatriske sygdomme
DE602005012993D1 (de) Einheit zur behandlung von pellets
DK0789567T3 (da) En fremgangsmåde til behandling af vaskulære hovedpiner
DK1558279T3 (da) Botulinumtoksin til behandling af ulcus pepticum og gastroesophageal reflux-sygdom
WO2006138127A3 (fr) Toxine botulinique et traitement de troubles primaires d l'humeur et de l'affecte
SE0203713D0 (sv) Novel compounds
EA200401160A1 (ru) Производные тиазола и оксазола, которые модулируют активность ppar
DK1694354T3 (da) Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin
DK1272208T3 (da) Anvendelse af VEGF 165 og homologer til at behandle neuron-sygdomme
ATE399557T1 (de) Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
NO20025405D0 (no) Modulatorer for TNF-alfa-signalisering
DK1545609T3 (da) Antistoffer rettet mod oxideret apolipoprotein B
NO20054700L (no) Anvendelse av et fibrat og orlistat for behandling av fedme
DK1492501T3 (da) Fremgangsmåder med anvendelse af lamellare legemer til terapeutiske formål
DK1438034T3 (da) Anvendelse af -phenyl-3-dimethylaminiopropanforbindelser til behandling af urininkontinens
DK1603584T3 (da) Aplidine til behandling af multipelt myelom
DK1729796T3 (da) Behandling af tryksår
DE602004024871D1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten